Studying Melatonin and Recovery in Teens

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age12-18
SponsorStanford University

About this trial

The goal of this feasibility clinical trial is to learn if melatonin can help teens having major musculoskeletal surgery by promoting healthy sleep. Melatonin is available as a dietary supplement that may be effective in promoting longer, higher quality sleep. This study will assess the feasibility and acceptability of melatonin for teens undergoing major musculoskeletal surgery, as well as determine optimal measured outcomes (sleep, pain, health-related quality of life) at short- and long-term follow-up.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 12-18 years

Participants undergoing elective major musculoskeletal surgery for eligible conditions

California state resident

Regular access to internet and smartphone

Disqualifiers

Prescription medication for premorbid insomnia

Cognitive impairment or developmental delay

Does not agree to a 1-week washout if taking over the counter supplements or other sleep aids prior to the start of the study medication

High risk for sleep related breathing disorder

Trial design

Design model

Parallel

Treatments tested in this trial

  • Fast-Dissolve Melatonin Pill

    Dietary supplement

    Participants in this arm will take 3mg of melatonin in fast-dissolve pill form daily during the specified study period.

  • Fast-Dissolve Placebo Pill

    Other intervention

    Participants in this arm will take 3mg of placebo in fast-dissolve pill form daily during the specified study period.

Treatment groups

45 Participants
are divided into 2 treatment groups
Group A: 3mg fast-dissolve pillPlacebo comparator 1 intervention
Group B: 3mg fast-dissolve pill (containing melatonin)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Treatment Adherence

Youth will self-report daily medication administration on the morning and evening diaries, including the study drug as well as opioid and non-opioid analgesic medications. Medication administration will also be extracted from the EMR during hospitalization. Adherence will be measured as the percentages of doses taken.

Time frame
Treatment phase of 14 days before surgery through 21 days after surgery (T2), and 7 days at 3-month follow-up (T3)
2

Study Acceptability

Youth and parent will complete ratings of treatment acceptability using a 5-point scale, ranging from 1 (Strong Dislike or Strongly Disagree) to 5 (Strongly Like or Strongly Agree). A higher score indicates greater study acceptability.

Time frame
Assessed one time at Day 21 post-op, and at 3-month follow-up (T3)
3

Enrollment and Retention

Research coordinators will record participant status at each stage including participants approached, assessed for eligibility, invited, consented, randomly assigned, and who received the intended treatment, and completed assessment timepoints, and will collect reasons for declining and dropout. Feasibility metrics will include enrollment rate and attrition rate.

Time frame
Pre-treatment (T1), treatment phase of 14 days before surgery through 21 days after surgery (T2), and 7 days at 3-month follow-up (T3)
4

Treatment Side Effects

Youth participants will be asked an open-ended question about side effects they may have experienced from the study drug. The rate of side effects of treatment will be self-reported by participants and extracted from EMR during hospitalization.

Time frame
Assessed one time at Day 21 post-op, and at 3-month follow-up (T3)

Secondary outcomes

1

Change in Sleep Quality

Youth will complete the Adolescent Sleep Wake Scale (ASWS), a 10-item measure of sleep quality over the past month rated on a 6-point Likert scale ranging from "Always" to "Never". The measure assesses five behavioral dimensions of sleep quality: (1) going to bed, (2) falling asleep/latency, (3) maintaining sleep, (4) re-initiating sleep, and (5) returning to wakefulness, and yields a total sleep quality score.

Time frame
Pre-treatment (T1) and one time at 3-month follow-up (T3)
2

Change in Peri-operative Sleep Quality

Youth will complete once daily online diaries assessing daily sleep quality in the morning. Sleep quality will be rated on an 11-point scale ranging from 0 (Extremely poor sleep) to 10 (Extremely good sleep). A higher score indicates higher quality sleep.

Time frame
Treatment phase of 14 days before surgery through 21 days post-op (T2) and 7 days at 3-month follow-up (T3)
3

Change in Sleep Duration

Youth will wear an actigraphy monitor to measure sleep duration. Youth will also report on sleep and wake times on the online morning diary, which will be used to assist with actigraphy scoring. Actigraphic sleep variables will include: minutes of estimated sleep, and sleep efficiency.

Time frame
Treatment phase of 14 days before surgery through 21 days post-op (T2) and 7 days at 3-month follow-up (T3)
4

Change in Health-related Quality of Life

Youth will complete the Pediatric Quality of Life Inventory (PedsQL), a 15-item measure that assesses self-reported physical, social, and emotional health-related qualify of life over the prior 7 days. The measure yields Physical Health, Psychosocial Health, and Total Health summary scores. The PedsQL is widely used and demonstrates good reliability for both the parent and child self-report measures. Scale scores range from 0 to 100. Higher scores indicate fewer difficulties (better) health-related quality of life.

Time frame
Pre-treatment (T1) and one time at 3-month follow-up (T3)

Other outcomes

1

Adverse Events

Youth and parents will be asked questions about adverse events.

Time frame
Assessed one time at 3-month follow-up (T3)
2

Concomitant therapy

Youth and parents will be asked open-ended questions about concomitant therapies the patient may have taken (use of sleep aids).

Time frame
Assessed one time at 21 days post-op (T2) and one time at 3-month follow-up (T3)
3

Pediatric Anxiety

Youth will complete the PROMIS Anxiety Short Form 8a, which assesses the pure domain of anxiety in children and adolescents (8 items) in the prior 7 days, with response options indicated on a 5-point scale. Higher scores indicate greater severity of anxiety. Response options range from 1 (Never) to 5 (Almost Always). Raw scores for anxiety and depression are obtained by summing the corresponding items' response values, and range from 8 to 40 with higher scores indicating higher distress.

Time frame
Assessed one time on day before surgery (T2)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Stanford University

Lead sponsor

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Collaborator